Viromer® BLUE

miRNA / siRNA transfection

Versatile reagent for standard and challenging cells. Fully compatible with suspension cells and 3D spheroids. Highly efficient and safe.

Selected cells might prefer GREEN.

Sufficient for the average number of * transfections in a 24-well format.


versatile miRNA and siRNA transfection reagent

Viromer® BLUE was developed for the siRNA transfection and is optimized for binding the size of small oligonucleotides like miRNA and siRNA. It is based on a medium sized branched polymer and the neutral charge of Viromer BLUE : miRNA and siRNA transfection complexes results in no aggregation and high performance in suspension cells like primary microglia cells. Viromer® BLUE achieves the best miRNA or siRNA transfection results in classical cell lines widely used in cell biology such as HEK-293, HeLa and CHO as well as in challenging primary cells like mesenchymal stem cells, macrophages, monocytes, myoblasts and hepatocytes. By using Viromer® BLUE a highly efficient miRNA and siRNA transfection is possible without the use of enhancers. Based on an active endosome escape mechanism siRNA transfection becomes more efficient compared to standard reagents as more of introduced siRNA/miRNA molecules reach the cytoplasma. Due to lowest toxicity and superior efficiency, Viromer® BLUE turns a hardly-possible miRNA and siRNA transfection into a superior one.

Excellent results in siRNA transfection of hard-to-transfect cells

Proprietary Viromer® BLUE miRNA and siRNA transfection technology has already convinced numerous research groups by providing excellent results on cell lines and primary cells that were thought to be impossible to transfect. siRNA transfection of human primary macrophages and human primary mesenchymal stem cells results in 70% knock down efficiency using Viromer® BLUE.

Knockdown in primary M2 macrophages after transfection with Viromer® BLUEKnockdown in primary mesenchymal stem cells after transfection with Viromer® BLUEKnockdown in adipocytes after transfection with Viromer® BLUE

For primary skeletal myoblasts, primary hepatocytes, RAW264.7 mouse macrophages, melanoma cells, Hs74T gastric carcinoma cells as well as glioblastoma cell lines NCH82 and NCH149 a siRNA transfection efficiency >90% can be achieved using Viromer® BLUE.

Knockdown in primary skeletal myoblasts after transfection with Viromer® BLUEKnockdown in primary hepatocytes after transfection with Viromer® BLUEKnockdown in melanoma cells after transfection with Viromer® BLUE


  • RNA interference with siRNA
  • regulation of protein expression via miRNA
  • cancer research
  • stem cell research
  • cell signaling

Features and Benefits

  • High transfection efficiency due to an active escape of Viromer® complexes from the endosome.
  • Great safety because Viromer complexes are non-charged, gentle on cells and compatible with serum and antibiotics.
  • Easy and fast transfection with consistent results ascribed to straightforward protocol including initial optimization.


  • Buffer BLUE, pH 7.2 is supplied with the kit
  • for research use only
  • store dry at 2-8°C

Publications for miRNA / siRNA transfection with Viromer® BLUE

Angiopoietin-like Protein 4 is an exercise-induced hepatokine in humans, regulated by glucagon and cAMP

Ingerslev et. al., Mol Metab., 2017

Integrated analysis of miRNA expression in response to Salmonella  Typhimurium infection in pigs.
Herrera Uribe - 2017
Prostaglandin E2 glyceryl ester is an endogenous agonist of the nucleotide receptor P2Y6.

Brüser et. al., Sci Rep., 2017

Carboxypeptidase E transmits its anti-migratory function in glioma cells via transcriptional regulation of cell architecture and motility regulating factors.

Armento et. al., Int J Oncol., 2017

FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.

Smith et. al., Sci Rep., 2017

The role of microRNA-5196 in the pathogenesis of systemic sclerosis.

Ciechomska et. al., Eur J Clin Invest., 2017

Effects of hypnotic bromovalerylurea on microglial BV2 cells.

Kawasaki et. al., J Pharmacol Sci., 2017

A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB.

Park et. al., Int J Oncol., 2017

Corneal stromal stem cells reduce corneal scarring by mediating neutrophil infiltration after wounding.

Hertsenberg et. al., PLoS ONE, 2017


Burai et. al., US Patent 20,170,050,967, 2017

Microglial complement receptor 3 regulates brainlevels through secreted proteolytic activity.

Czirr et. al., J Exp Med., 2017

The RNA-binding protein Tristetraprolin (TTP) is a critical negative regulator of the NLRP3 inflammasome.

Haneklaus et. al., JBC, 2017

Downregulation of Lnc-Spry1 mediates TGF-β-induced epithelial–mesenchymal transition by transcriptional and posttranscriptional regulatory mechanisms.

Rodríguez-Mateo et. al., Cell Death & Differentiation, 2017

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures.

Morrison, J. Vis. Exp., 2016

Loss of the Tumor Suppressor NKX3.1 in Prostate Cancer Cells is Induced by Prostatitis Related Mitogens

Decker, J Clin Onc Exp Onc, 2016

Lysophosphatidylcholines activate PPARδ and protect human skeletal muscle cells from lipotoxicity.

Klingler, Biochim Biophys Acta., 2016

IFN-ε protects primary macrophages against HIV infection.

Tasker, JCI Insight., 2016

BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.

Ciechomska, Sci Rep., 2016

GSK-3β controls NF-kappaB activity via IKKγ/NEMO.

Medunjanin, Sci Rep., 2016

STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.

Yan, Cell Rep, 2016

Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression.

Ellert-Miklaszewska et. al., Oncogene 2016

Folate Receptor β Regulates Integrin CD11b/CD18 Adhesion of a Macrophage Subset to Collagen.

Machacek et. al., J Immunol., 2016

Analyse des signalinduzierten Verlusts des Tumorsuppressors NKX3.1 in Prostatitis und Prostatakarzinomzellen
Decker, 2016
ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers
Madan et. al., Am J Cancer Re., 2016
Glutathione adducts induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1α and improve limb revascularization.

Watanabe et. al., Proc Natl Acad Sci U S A., 2016

cGAS Senses Human Cytomegalovirus and Induces Type I Interferon Responses in Human Monocyte-Derived Cells

Paijo et. al., PLoS Pathog., 2016

microRNAs constitute a negative feedback loop in Streptococcus pneumoniae induced macrophage activation.

Griss et. al., J Infect Dis, 2016

An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway.

Robertson et. al., PLoS Biol, 2016

Granulocyte colony-stimulating factor (G-CSF): A saturated fatty acid-induced myokine with insulin-desensitizing properties in humans

Ordelheide et. al., Molecular Metabolism, 2016

Histone demethylation and TLR8-dependent crosstalk in monocytes promotes trans-differentiation of fibroblasts in systemic sclerosis via Fra2.

Ciechomska, Arthritis Rheumatol, 2016

Oxidized LDL-bound CD36 recruits an Na⁺/K⁺-ATPase-Lyn complex in macrophages that promotes atherosclerosis.

Chen et. al., Sci Signal., 2015

Inhibition of adipogenic differentiation of human SGBS preadipocytes by androgen-regulated microRNA miR-375.

Kraus, Mol Cell Endocrinol., 2015

Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data.

Rane, Br J Cancer, 2015

TRIM25 has a dual function in the p53/Mdm2 circuit

Zhang, Oncogene, 2015

MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity.

Salama et. al., PLoS One, 2014

Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein ZFP36L1 in malignant B cells.

Zekavati et. al., PLoS One, 2014